The safety of M-CSF was assessed in cynomolgus monkeys in an intravenous dosing regimen. Exposure (AUC 0 _ 24 ) multiples (monkey vs human) were calculated using the no observable adverse effect level (NOAEL) observed in this study and correlated with known M-CSF-induced toxicities in a previous continuous intravenous infusion (civ) study in monkeys. M-CSF was administered by daily intravenous infusion (2 h) to cynomolgus monkeys (2/sex/ group) at 0.1, 0.3,0.7, and 1.0 mg/kg/day, for 28 consecutive days. Control animals (2/sex) received placebo. The 0.7 mg/kg/day group was held for an additional 4-week recovery period. Criteria evaluated included physical observations, ophthalmoscopy, electrocardiography, body weight, food consumption, clinical pathology, antibody formation, pharmacokinetics, necropsy, organ weights, and histopathology. The only effect previously seen in monkeys after intravenously administered M-CSF occurred in animals in the 0.7 and 1.0 mg/kg/day groups. They exhibited a slight decrease in platelets between days 4 and 12 with subsequent recovery. No effects related to M-CSF administration were evident in macroscopic or microscopic evaluations and there was no evidence of anti-M-CSF antibody production. M-CSF at all dose levels was completely eliminated within each dosing interval with no accumulation. Clearance of M-CSF was enhanced during the first week of dosing, but returned to baseline clearance levels by day 27. This dosing regimen was shown to be remarkably free of toxicities noted in a previous monkey study where M-CSF was given by civ at similar daily doses. At the high dose, which was considered to be the NOAEL, the AUCo^ was 40-fold greater than the AUC 0 _24 in clinical trials where 2.0 mg/m 2 was administered by a daily 2-h infusion. C 1998 Society or Toxicology.
1 Presented at the 34th Annual Meeting, Society of Toxicology (Poster Session 1995).
Macrophage colony-stimulating factor, M-CSF (Macrolin 2 ), a human recombinant hematopoietic growth factor purified from E. coli (Kawasaki et al, 1985) , has been shown to selectively stimulate survival, proliferation, differentiation, and activation of cells from the mononuclear phagocyte lineage, specifically monoblasts, promonocytes, monocytes, and macrophages (Pluznik and Sachs, 1965; Bradley and Medcalf, 1966; Ichikawa et al, 1966) . Activated mononuclear cells have also shown enhanced antifungal (Vitt et al, 1994) and antibacterial properties (Cross et al, 1991) and the ability to promote host defense (Cross et al., 1991) . M-CSF has also demonstrated activity in wound healing (Middleton and Aukerman, 1991) and in tumor-bearing (Bock et al., 1991) and osteopetrotic animal models (Marks et al., 1993; Thiede et al., 1996) .
Recombinant M-CSF has a molecular mass of 45 kDa. It is purified from Escherichia coli inclusion bodies and renatured in vitro to form a dimeric protein containing seven disulfide bonds (Halenbeck et al., 1989) . The specific activity of this nonglycosylated, truncated M-CSF is equal to that of glycosylated native M-CSF purified from human urine or recombinant M-CSF-a secreted from Chinese hamster ovary cells.
A previous study of M-CSF (civ) in monkeys (Johnson et al., 1993) reported toxicity related to the biological effect of M-CSF, specifically lymphocytosis and multiorgan tissue infiltration of monocytes. In addition, thrombocytopenia was observed at the highest dose level. Although the mechanism associated with the induction of thrombocytopenia has not been fully elucidated, this effect is dose and schedule dependent in animals and humans (Johnson et al., 1993; Nemunaitis etai, 1991; Zamkoff era/., 1992; Sanda et al, 1992) and may be dose limiting in humans (Nemunaitis et al, 1991) . The purpose of this current study was to assess the potential toxicity of M-CSF in the cynomolgus monkey when administered by a daily 2-h i.v. infusion for 28 days. This dosing schedule was similar to a clinical regimen administered to patients in anti-fungal clinical trials (Nemunaitis et al., 1991 Nemunaitis, 1993) and daily doses were comparable to the civ monkey study (Johnson et al., 1993) . This study was conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology at Huntingdon Life Sciences (East Millstone, NJ).
METHODS
Twenty cynomolgus monkeys (2/sex/group) were dosed via i.v. infusion with 0.1, 0.3. 0.7, and 1 mg/kg/day of M-CSF (Macrolin) or placebo once daily for 2 h/day for 28 consecutive days. The dose volume, 5 ml/kg/day, was equalized between all groups. Animals in the 0.7 mg/kg/day group were evaluated after an additional 4-week treatment-free period. These dose levels were similar to those of a previous study (Johnson et al, 1993) , where 0.7 mg/kg/day civ was the high dose. Significant toxicological effects occurred at 0.7 mg/kg/day level in the civ study; therefore, it was selected for additional observation here. Body weight for all animals ranged from 2.5 to 4.5 kg. All animals underwent surgical implantation of an infusion catheter into the femoral vein which was passed retrograde into the vena cava approximately 1 week prior to the initiation of dosing. An antibiotic (Phipen 300,000 IU/ml) was administered to each animal on the day prior to and for 5 days after surgery.
Data acquisition and sample collection. Viability checks were performed twice daily from pretest through the recovery period. Clinical observations were conducted daily just prior to, during, and at the termination of the infusion. Detailed physical examinations were conducted pretest, at termination, and upon recovery. Blood and urine samples were collected for all animals before (Pretest 1) and after surgical implantation (Pretest 2) of the infusion catheter and at selected intervals throughout dosing and recovery. Blood samples were collected via femoral venipuncture from unanesthetized monkeys. Hematology samples were obtained for pre-and postsurgery, and on days 2, 4, 8, 10, 15, 22, 27 , and during the last week of recovery (days 50-58). Clinical chemistry and coagulation samples were collected pre-and postsurgery, days 16, 28, and during the last week of recovery (days 50-58). Samples for pharmacokinetic analysis were collected just prior to the first dose administration and at selected intervals on days 1, 8, 15, 22, and 27. The pharmacokinetic sampling schedule was modified for each dose and day to account for expected differences in the shape of the serum profiles based on previous experience with M-CSF (Bauer et al, 1994) . Samples for antibody analysis were obtained pre-and postsurgery and prior to dosing on days 8, 15, 22, 27, and during the last week of recovery (days 50-58). Urinalysis samples were obtained pre-and postsurgery and at day 29 and during the last week of recovery (days 50-58). Body weight and visual food consumption data were collected prior to surgery and postsurgery (body weights only) and then weekly thereafter until termination or recovery euthanasia. Electrocardiograms were conducted pre-and postsurgery, during week 2 (days 8 to 14), at termination (day 29), and upon recovery euthanasia (day 58). Ophthalmic examinations were conducted presurgery, at termination (day 29), and upon recovery euthanasia (day 58).
Postmortem. Each animal was given a complete necropsy examination. The following organs were weighed: adrenal glands, brain, heart, kidneys, liver, ovaries, pituitary gland, prostate gland, spleen, testes with epididymides, thyroid, and parathyroid glands on days 29 (0, 0.1, 0.3, and 1.0 mg/kg groups) and 58 (0.7 mg/kg group). The following tissues were collected and evaluated for all animals for histopathological alterations (H & E staining): brain, spinal cord, nerve, heart, aorta, trachea, esophagus, lung, thymus, spleen, liver, gallbladder, salivary gland, kidney, stomach, duodenum, pancreas, jejunum, ileum, cecum, colon, rectum, multiple lymph nodes, testis, epididymides, prostate gland, seminal vesicle, urinary bladder, ovary, uterus, vagina, adrenal gland, pituitary gland, thyroid, parathyroid gland, eye, optic nerve, skeletal muscle, skin, mammary gland, catheter and catheter tip, infusion site, sternum, bone marrow, femur, and tissue lesions and or masses.
Dose preparation. Recombinant M-CSF is a lyophilized product, formulated in mannitol, sucrose, and glycine in sodium citrate without a bacteriostatic agent, manufactured and formulated by Chiron Corporation. M-CSF (Lot FDP2002B) and placebo (Lot FXP2O05D) were reconstituted with sterile water for injection, USP, and diluted with sterile saline for injection, USP, to make the required dosing solutions. The material was then placed in a Viaflex bag and attached to an infusion pump, which was connected to a tether system with a swivel, which was held in place by a jacket wom by the animal. After dosing, sterile saline was infused to the volume of the catheter dead space. All catheters were heparin locked (100 IU/ml) between doses. Assays of dosing solutions by enzyme immunoassay (ELISA) showed M-CSF concentrations that were 89% of expected.
Assay. Serum M-CSF concentrations in the pharmacokinetic samples were measured by ELISA. Experimental samples or calibration standards (prepared in pooled monkey serum) were diluted in fetal bovine serum and transferred in duplicate to 96-well plates coated with antibody to M-CSF. After a 2-h incubation, serum was washed off the plate and a horseradish peroxidaseconjugated anti-M-CSF antibody was added to each well. Following a second incubation with a horseradish peroxidase conjugated anti-MCSF antibody a chromogenic substrate was added to each well. Color absorbance was quantitated spectrophotometrically (450 nm). The minimum quantifiable limit of the assay was 0.49 ng/ml, determined from the concentration in the lowest standard (0.049 ng/ml) multiplied by the minimum serum dilution (1:10).
Antibodies to M-CSF were measured by adding serum in duplicate to 96-well plates coated with M-CSF. Following a second incubation with horseradish peroxidase-conjugated goat anti-monkey immunoglobulin, a colorimetric substrate was added to the wells. Samples were scored positive if the colorimetric signal exceeded that of a positive reference standard.
Pharmacokinetic analysis. Serum concentration-time data were analyzed by noncompartmental methods using macros written for Microsoft Excel v. 4.0, (Microsoft Corporation, Redmond, WA). The macros were previously validated by comparing results against values calculated with a hand calculator and by accurately reproducing values reported in the literature. The terminalphase half-life (t 1/2) of the M-CSF serum concentration-time curve was calculated from the ratio 0.693/slope, where the slope was obtained by linear regression of the natural log-transformed serum concentrations at the last three (or in some cases, two) time points in each data set. The area under the serum concentration-time curve from the time of dosing to the last nonzero concentration (AUC 0 _ UM1 ) was calculated by the linear trapezoidal rule. The remaining area from the time of the last nonzero concentration to the end of the 24-h dosing interval was estimated from the terminal-phase half-life. The area from time zero to 24 h (AUCQ.^) was calculated as slope where d' Un and £ 24 represent the extrapolated concentrations at tlast and 24 h, based on the slope used to calculate the terminal-phase half-life. Overall, the extrapolated portion of each curve accounted for less than 10% of the total area.
Statistics. The parameter AUCo_ 2 4 was dose-normalized (i.e., AUCo_ 24 / dose) for statistical comparisons. Dose and gender effects on dose-normalized AUCo_ M were assessed by repeated measures analysis of variance (ANOVA) using the MIXED procedure in SAS (v. 6.08; SAS Institute, Cary, NQ with the significance level set at 0.05. The sources of variation evaluated in the statistical model were dose level, gender, and crossed effects between dose level and gender, day and gender, day and dose level, and day, gender, and dose level. Time-dependent changes in M-CSF pharmacokinetics were assessed using multiple one-sided paired t tests to compare dose-normalized AUCo_24 values from days 8, 15, 22, or 27, successively, against Day 1. Because of the increased probability of a type 1 error associated with multiple 
RESULTS
All animals survived treatment except one female animal in the 0.1 mg/kg/day group that was euthanized in a moribund condition on day 24. Clinically this animal exhibited a marked increase in the percentage of neutrophils prior to euthanasia; the cause of death for this animal was septicemia, which was confirmed histologically. This animal had undergone two additional reimplantations of the infusion catheter, and these additional surgical procedures probably contributed to the septic condition in this animal.
Hematology findings which were attributed to M-CSF treatment were a decrease in mean platelet values when compared to pretest levels in the 0.7 and 1.0 mg/kg/day groups; beginning on day 4 through day 10 with the maximum decrease occurring between days 8 and 10 (Table 1) ; this decrease was slightly more evident in females than males. Platelet values at Day 8 were 247 and 197 in the two females and 345 and 170 in the two males. This slight decrease in platelets was not considered to be clinically relevant.
There was no change in the absolute monocyte count for either sex in the 0.7 or 1 mg/kg/day groups. Other findings observed but judged not to be related to M-CSF were an increase in activated partial thrombopastin time (APPT) in one male receiving 0.7 mg/kg/day on day 28 (49.4 s compared to the historical lab value for males of 19.5 ±1.6 s). This value returned to pretest levels during the recovery phase. The only clinical chemistry finding which may have been related to M-CSF treatment was a decrease in albumin in the males in the 0.7 mg/kg/day group at study termination which resulted in a decrease in the albumin/globulin ratio from 0.9 ±0.1 g/dl to 0.6 ±0.1 g/dl. However, this value returned to the pretest level during recovery.
Representative serum concentration-time profiles are shown in Fig. 1 . Across the dose range, mean (±SD) maximum serum M-CSF concentrations {C max ) on Day 1 increased from 1.8 ± 0.2 ng/ml at 0.1 mg/kg/day to 19.0 ± 4.0 ng/ml at 1.0 mg/kg/ day ( Table 2) 0.51 ± 0.12 h in the low dose group to 2.03 ± 0.69 h in the high dose group. Doses of M-CSF were completely eliminated within each 24-h dosing interval.
The parameter AUC 0 _ 24 describes the systemic exposure to a drug in a 24-h period and is inversely proportional to clearance. The AUCo_24 at each dose level was normalized to the dose in order to compare exposure across dose levels by ANOVA or t test. In this study, the dose-normalized AUCo_ 24 was disproportionately larger at higher doses than at lower doses (Fig. 2) , indicating a decrease in clearance at higher doses. The systemic exposure also appeared to be consistently smaller in females than in males, indicating higher clearance in females. These trends were confirmed by ANOVA, where dose and gender were both found to have a statistically significant influence on AUC 0 _ 24 during the 27 days of study (p < 0.05). No significant interactions were detected between gender and dose level, or between day and gender, day and dose level, or day, gender, and dose level. The dose-normalized AUC 0 _ 24 decreased between Days 1 and 8 and then gradually increased between Days 8 and 27 (Fig. 3) . By paired t test, dosenormalized AUC 0 _ 24 values were significantly smaller on Days 8, 15, and 22 than on Day 1 (p < 0.0125), but were similar to baseline values on Day 27 (Table 2 ). These changes were consistent with enhanced clearance during the first week of M-CSF administration followed by a gradual return to the baseline clearance rate. The pattern of decline and recovery was similar in male and females.
Antibody analysis indicated that only one animal in the 0.1 mg/kg dose group developed a low antibody titer during dosing, on Day 8, but this increase was transient and returned to baseline levels without a detectable effect on pharmacokinetics. There was no other evidence of antibody production in any monkey.
There were no M-CSF related findings for clinical observations, body weight, food consumption, urinalysis, electrocar- diography, ophthalmology, necropsy observations, organ weights, and histopathology.
DISCUSSION
The effects of M-CSF administration in monkeys by 2 h i.v. infusion for 28 days on hematological parameters, physical signs, tissue histology and organ weights differed in severity of effect from those previously seen at similar daily doses given by civ. Although the number of animals used in the civ study was small, the data suggest that the 2-h i.v. infusion for 28 days was better tolerated than the 14-day civ dosing regimen.
Hematological changes observed at termination (day 15) in the 14-day civ dosing regimen of M-CSF (Johnson et al., 1993) included an 8 to 25% reduction when compared to baseline values in all red blood cell parameters (RBC, HBG, HCT) for all M-CSF treated groups; a substantial increase of 74 to 154% in white blood cell count (WBC) at doses of >0.1 mg/kg/day with a rise in monocyte counts of 199 to 544% for all treated groups; and a 3 to 89% decrease in platelet counts for all treated groups except for the 0.1 mg/kg/day group (Table 1) . This contrasts to the 28-day 2-h i.v. infusion of M-CSF data collected at termination (day 27), which suggests a more modest reduction when compared to baseline values in RBC parameters of 3 to 18% for males at doses >0.7 mg/kg/day with no decreases in RBC parameters for females at any dose level. A lesser increase in WBC was observed in both males and females, specifically at 8 to 32% increase for the males in the 0.1 and 0.7 mg/kg/day groups; and a 20 to 40% increase for the females in the 0.1 and 1.0 mg/kg/day groups. Also there were slight increases in absolute monocyte counts of 49 to 63% for the males in the 0.1 to 0.7 mg/kg/day groups and smaller increases in monocyte counts of 15 to 30% for the females in the 0.1 and 1.0 mg/kg/day groups only. In addition, a much smaller change in platelet counts was observed; in males, a decrease from baseline of 16% for the 0.1 mg/kg/day group, with an increase in platelet counts of 3 to 35% for doses >0.0.3 mg/kg/day. In the females there was a slight decrease in platelet count of 16 to 22% in all dose groups. The hematological changes for the 2-h i.v. infusion dosing regimen were within the laboratory's historical range for control animals of this species and were not considered to be clinically relevant. Overall, the decreases in RBC parameters and platelets and increases in WBC and absolute monocyte counts were more pronounced in terms of severity in the 14-day civ dosing regimen than the 2-h i.v. infusion dosing regimen.
Notably, there were no histological findings or changes in organ weights for any animal in the 28-day 2-h i.v. infusion study at termination or at recovery sacrifice. In addition, there was no corresponding monocyte increase or mononuclear infiltration of any tissue as noted before. It can be concluded that M-CSF administration for a 2-h period for 28 days was associated with fewer and or less severe toxicities than the 14-day civ regimen at similar daily doses in monkeys.
The nonlinear relationship between AUC 0 _ 24 and dose suggested a saturable clearance mechanism by which the systemic exposure increased at higher doses as serum clearance was reduced. Evidence of such a mechanism operating in parallel with a linear, nonsaturable pathway has been described for M-CSF in several species including humans (Bauer et al., 1994; Timony et al, 1990; Zamkoff et al., 1992; Redmond et al., 1992) . In rats, the saturable pathway has been shown to be mediated by cells of the monocyte/macrophage lineage (Bauer et al., 1994) and by cells bearing specific M-CSF receptors (Timony et al., 1990) . The conclusions of the present study support the model of M-CSF clearance developed in earlier studies. This study also revealed higher clearance in female cynomolgus monkeys than in males. It is not known whether gender-related differences in M-CSF clearance exist in other species, including humans.
The significant decrease in AUC 0 _ 24 between Days 1 and 8 implied that the nonlinear clearance pathway was up-regulated in response to chronic exposure to M-CSF. Enhancement of M-CSF clearance has been observed previously in cynomolgus monkeys (Timony et al., 1990) , and humans (Redmond et al., 1992; Chiron unpublished data) , and has been attributed to proliferation of M-CSF receptors and/or receptor-bearing cells. Notably, in the current study the clearance returned to the baseline rate by Day 27. This reversal was not observed in earlier, short-term studies.
Plasma concentration-time curves of M-CSF in monkeys (this study) and humans are shown in Fig. 4 . The human data are derived from bone-marrow transplant patients in antifungal trials given M-CSF at 2 mg/m 2 over 2 h. The C max by this regimen was 350 ng/ml with an AUC estimated at 1.2 /ig-h/ml. In this study, the no observable adverse effect level (NOAEL) was 1.0 mg/kg/day. The 1.0 mg/kg/day dose (approximately 12 mg/m 2 ) produced an average C max on day 1 of 19.0 p-g/ml and an average AUC on day 1 of 57.2 /j-g-h/ml (Table 2 and Fig. 4) . A comparison of AUCs indicate a 40-fold safety margin based on exposure from comparable 2-h infusion regimes.
Considering the large safety factor and that the biological effects (thrombocytopenia, anemia, leucocytosis) can be monitored clinically and are reversible upon cessation of dosing, the safety of M-CSF administration by daily 2-h i.v. infusion for 28 days in cynomolgus monkeys supports the clinical regimen of a daily 2-h infusion of M-CSF in humans. CONCLUSION M-CSF given by daily 2-h intravenous infusions for 28 days in the cynomolgus monkey produced no significant toxicity. The NOAEL was considered to be 1.0 mg/kg/day. This contrasts to significant toxicity (related to biological activity) when M-CSF was administered by civ for 14 days at the same daily dose. The biological effects (reduction in platelets) noted in the 0.7 and 1.0 mg/kg/day groups were not considered to be clinically relevant in this animal model. M-CSF was not immunogenic at the doses and regimen used in this study. Doses of M-CSF administered (0.1 to 1.0 mg/kg/day) were completely eliminated within each 24-h dosing interval throughout this study. M-CSF clearance although enhanced during the first week of dosing returned to the baseline rate by the end of dosing and was apparently higher in females than males. There is an estimated 40-fold safety margin (based on exposure) between the NOAEL administered to cynomolgus monkeys and the dose administered to humans in antifungal trials.
